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Abstract  30 
 In ocular surface inflammatory diseases, such as dry eye disease, long-term 31 
symptom relief requires targeting the inflammation itself rather than treating only the 32 
surface-associated dryness with artificial tears. Therefore, we included an anti-33 
inflammatory agent in an unpreserved liposome-based (LP) formulation used as 34 
artificial tears. Our aim was to characterize and study its in vitro and ex vivo cell uptake 35 
and functionality. Human corneal epithelial (HCE) cells were used to study MPA-LP-36 
induced effects after 60 min of exposure, using blank LP and non-LP MPA formulations 37 
as controls. A fluorescent labeled LP formulation was used to determine uptake by 38 
HCE cells and localization in ex vivo porcine corneas. The LP formulation complied 39 
with the required physicochemical properties and had no cytotoxicity on HCE cells after 40 
60 min of exposure. HCE cells showed LP-associated fluorescence at 24, 48, and 72 h 41 
after 60 min of exposure, and the LP-associated fluorescence was uniformly distributed 42 
throughout the porcine corneal epithelium immediately after 5 min of exposure. MPA-43 
LP increased protein expression and nuclear translocation of progesterone receptor in 44 
comparison with controls as determined by Western blotting and immunofluorescence. 45 
Moreover, MPA-LP significantly reduced the cell proliferation rate and IL-6 and IL-8 46 
production 48 h after the exposure period, as determined by the alamarBlue assay and 47 
ELISA, respectively. None of these effects were evident in blank LP-exposed cells and 48 
non-LP MPA formulation reduced only IL-6 production. Our results suggest that the LP-49 
based formulation, used to replenish the lipids of the tear film, can be loaded with anti-50 
inflammatory agents that can be delivered into the cells and activate specific drug 51 
receptors. These agents can reduce inflammatory cytokine production and may be 52 
effective in the treatment of inflammatory processes associated with ocular surface 53 
diseases. 54 
 55 
Keywords 56 
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Abbreviations 60 
BAC: benzalkonium chloride 61 
C6: coumarin-6 62 
DED: dry eye disease 63 
DMEM/F12: Dulbecco’s Modified Eagle Medium + F12 medium mixture 64 
EE: encapsulation efficiency 65 
ELISA: enzyme-linked immunosorbent assay 66 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 67 
HCE: human corneal epithelial  68 
HPLC: high performance liquid chromatography 69 
IL: interleukin 70 
LP: liposome 71 
MPA: medroxyprogesterone acetate 72 
PBS: phosphate buffered saline 73 
PC: phosphatidylcholine  74 
SEM: standard error of the mean 75 
TNFα: tumor necrosis factor-alpha 76 
XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 77 
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1. Introduction 79 
 Eye tissues are affected by diverse inflammation-based diseases that can be 80 
devastating as eyesight is impaired. A paradigm of such inflammatory disorders is dry 81 
eye disease (DED), a common age-related ocular pathology that results from 82 
dysfunction of the ocular surface and/or tissues that produce the tears. The primary 83 
effects of patients with DED are impaired functional visual acuity and low quality of life. 84 
At the molecular level, the main reason of these effects is an underlying inflammation 85 
process that profoundly alters the ocular surface tissues and the tear film. Recent 86 
research has led to innovations in the pharmacological treatment of DED. These 87 
advances have focused on tear replacement or tear preservation with novel artificial 88 
tears, topical and systemic anti-inflammatory and immunosuppressive therapy, and 89 
even the use of medical devices in the more severe grades of the disease (Pflugfelder 90 
et al. 2000). Despite significant progress in these treatments, the disease in many 91 
patients is not fully alleviated. Although current treatments with artificial tears are the 92 
first step for symptomatic relief, the ongoing inflammation is not addressed. The use of 93 
drug delivery systems is of great interest to improve the pharmacological management 94 
of DED because they can encapsulate active agents, direct them to the target 95 
tissue/cells, and release the cargo in a controlled fashion (Diebold and Calonge. 2010, 96 
Patel et al. 2013). In topically administered drugs, these devices overcome drawbacks 97 
such as low bioavailability due to the tear film barrier, rapid drainage, and poor corneal 98 
permeation.  99 
Among drug delivery systems, liposomes (LPs), which are vesicles containing an 100 
aqueous core and delimited by a membrane-like lipid bilayer, ensure good biological 101 
compatibility and reduced toxicity. The existence of an aqueous core and the lipid 102 
bilayer confers the ability to encapsulate both hydrophilic and lipophilic compounds with 103 
improved drug stability. LPs have been employed to improve drug transport across the 104 
cornea (Di Tommaso et al. 2012) with prolonged drug effect (Hathout et al. 2007, Law 105 
et al. 2000). The idea of using LPs as carriers for topically administered anti-106 
inflammatory drugs was first reported in 1982 (Schaeffer and Krohn. 1982) and has 107 
been continuously revised (Lim et al. 2015). Corticosteroids are potent anti-108 
inflammatory agents, poorly soluble in aqueous solution, which makes them good 109 
candidates for being encapsulated in drug delivery systems. However, with prolonged 110 
treatment, the potent activity of these drugs often causes adverse effects, such as 111 
increased intraocular pressure or cataract formation. For this reason, synthetic “soft” 112 
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anti-inflammatory steroids, like medroxyprogesterone acetate (MPA), are frequently 113 
prescribed for topical administration in the eye.  114 
Taking all of this information into account, our aim was to prepare and characterize 115 
a LP-based formulation loaded with the anti-inflammatory agent MPA that could be 116 
used as topically instilled artificial tears. Prior to proceeding with in vivo studies, it was 117 
necessary to determine by in vitro studies how corneal epithelial cells take up the drug 118 
delivery system and the encapsulated drug. Then, we asked whether or not the 119 
encapsulated drug was delivered into the cells and activated glucocorticoid and 120 
progesterone receptors, eliciting an anti-inflammatory effect in an in vitro inflammation 121 
model of human corneal epithelial cells. 122 
 123 
2. Materials and methods 124 
2.1. Materials and equipment 125 
All materials used in this study were purchased from Sigma-Aldrich (St. Louis, MO) 126 
except as follows: Phospholipon 90G, >95% of phosphatidylcholine (PC), was 127 
purchased from Lipoid GmbH (Cologne, Germany) and trehalose was acquired from 128 
Cymit Química S.L. (Barcelona, Spain). The MPA-commercial, non-LP formulation or 129 
reference formulation Colircusi Medrivas® was from Alcon Cusi S.A. (Barcelona, 130 
Spain). Dulbecco’s Modified Eagle Medium (DMEM)/F12 and some of its supplements, 131 
such as fetal bovine serum, penicillin, and streptomycin were from Invitrogen-GIBCO 132 
(Inchinnan, UK). Human epidermal growth factor and bovine insulin were from 133 
Invitrogen (Eugene, OR). Cell culture plates and multichamber Permanox® or Glass® 134 
slides were from Nunc (Roskilde, Denmark). For Western blot experiments, the 135 
bicinchoninic acid assay was from Pierce (Rockford, IL) and acrylamide and Tris-136 
buffered saline were purchased from Bio-Rad Laboratories (Hercules, CA). For 137 
immunocytochemistry and Western blotting, mouse monoclonal primary antibodies for 138 
glucocorticoid and progesterone receptors were from Abcam (Cambridge, UK), and the 139 
antibody for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was from Santa 140 
Cruz Biotechnology (Santa Cruz, CA). Fluoromount-G™ mounting media was from 141 
SouthernBiotech (Birmingham, AL). The alamarBlue® colorimetric indicator assay was 142 
from AbD Serotec (Oxford, UK). Tumor necrosis factor alpha (TNFα) was from 143 
PeproTech (London, UK). Human interleukin-6 (IL-6) and IL-8 enzyme-linked 144 
immunosorbent assay (ELISA) kits were from Diaclone (Bensançon, France). The 145 
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Lipex Extruder® was from Lipex Biomembrane™ (Vancouver, Canada) and the particle 146 
size analyzer Zetatrac® was from Microtrac-Europe GmbH (Meerbusch, Germany). The 147 
high performance liquid chromatography (HPLC) Waters 600 E, binary HPLC pump, 148 
717 Plus autosampler, in-line degasser, and 486 λ absorbance detector was from 149 
Waters (Barcelona, Spain) and the Mediterranean Sea® C18 100 Å 5-µm column (150 150 
mm by 4 mm) from Teknokroma, S.A. (Barcelona, Spain). The osmometer K-7000 was 151 
from Knauer (Berlin, Germany) and the thermostatically controlled rheometer 152 
Rheostress RS1 was from Haake Technik GmbH (Düsseldorf, Germany). The 153 
SpectraMAX® M5 multidetection microplate reader and the SoftMax Pro 4.8 software 154 
used for absorbance and fluorescence measurements were from Molecular Devices 155 
(Sunnyvale, CA). The Leica DMI 6000B microscope and the LAS AF Lite software and 156 
ImageJ software v. 1.49 (http://imagej.nih.gov/ij/) used to visualize and analyze 157 
fluorescence micrographs, were from Leica Microsystems (Wetzlar, Germany) and 158 
from National Institutes of Health (Bethesda, MD), respectively. Final fluorescence 159 
micrographs were minimally adjusted in terms of brightness and contrast using Adobe 160 
Photoshop version 8.0.1. The ChemiDoc XRS system and the Quantity One software 161 
used to visualize the acrylamide gel and to analyze the resulting images were from Bio-162 
Rad Laboratories. The IBM SPSS Statistics version 23.0 software used for statistical 163 
analyses was from IBM Corp. (Armonk, NY). 164 
 165 
2.2. Liposomal formulation preparation and fluorescent labeling  166 
LP formulation composed of PC, cholesterol, vitamin E, and MPA at a molar ratio 167 
13:3:0.2:0.3 was prepared by the solvent evaporation technique as previously 168 
described (Vicario-de-la-Torre et al. 2014). The film formed was hydrated with a 169 
dispersion solution comprised of borate buffer solution (135.5 mM) containing trehalose 170 
(42.5 mM). The MPA-LP formulations were extruded through a size-controlled 0.22-µm 171 
pore size polycarbonate membrane for ten cycles under nitrogen pressure (≤200 psi) to 172 
obtain lipid vesicles with a unimodal size distribution. Final PC and MPA concentrations 173 
in the resultant dispersion were 20 mg/mL and 200 µg/mL, respectively.  174 
To obtain fluorescently-labeled LP formulation, the lipid mixture containing 175 
coumarin-6 (C6) instead of MPA was dissolved in chloroform, and the C6-LP 176 
formulation was obtained following the protocol described above. Fluorescent C6-LP at 177 
a final C6 concentration of 20 µg/mL was used in human corneal epithelial (HCE) cells 178 
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and ex vivo porcine corneas (see sub-section 2.6 below). To determine LP-associated 179 
fluorescence, a suspension of C6 (not in liposomes) obtained from the supernatant 180 
after C6-LP centrifugation (49,263 g for 60 min at 10ºC) was used as the control. 181 
 182 
2.3. Characterization of liposomal formulation 183 
2.3.1. Particle size distribution and encapsulation efficiency  184 
Particle size distribution of blank, MPA-, and C6-LP formulations were measured by 185 
dynamic light scattering using a particle size analyzer at room temperature.  186 
To determine the encapsulation efficiency, the LP formulation was centrifuged 187 
(49,263 g for 60 min at 10ºC), and the supernatant was then analyzed by HPLC at 188 
40ºC. Isocratic MPA analysis was performed with a mobile phase of 189 
acetonitrile/tetrahydrofurane/ultrapure milliQ water (45/10/45), a flow rate of 1 mL min-1, 190 
and detection at 254 nm. The retention time was 12.5 min. This analytical procedure, 191 
described in Pharmacopeia (Shabir. 2003), was previously validated in our laboratory 192 
with regard to linearity, precision, and accuracy parameters. Encapsulation efficiency 193 
(EE) was calculated as follows:  194 
 =
0 − 1
0
∗ 100 
Where C0 and C1 were the concentration of the drug in the LP dispersion and in the 195 
supernatant after centrifugation.  196 
2.3.2. pH, osmolarity, and viscosity measurements 197 
The pH of the MPA- and C6-LP formulations was measured using a pH meter in 198 
triplicate at room temperature. 199 
Osmolarity was analyzed by a vapor pressure osmometer and performed in triplicate 200 
at 33ºC, equivalent to the ocular surface temperature (Purslow and Wolffsohn. 2005). 201 
Viscosity was measured using a thermostatically controlled rheometer. Viscosity 202 
was measured when the steady state was reached with shear rates increasing from 0 203 
to 1000 s-1. All determinations were made in triplicate at 33ºC.  204 
 205 
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2.4. Culture conditions and liposomal formulation exposure 206 
The HCE cell line (Araki-Sasaki et al. 1995) was cultured in DMEM/F12 medium 207 
supplemented with 10% fetal bovine serum, 5,000 U/mL penicillin/streptomycin, 10 208 
ng/mL human epidermal growth factor, and 5 µg/mL insulin. Cells from passages 32 to 209 
38 were used. 210 
Cells were grown until confluence and washed in supplement-free culture medium. 211 
Then, the LP formulations were diluted in supplement-free culture medium to get a final 212 
PC concentration of 5 mg/mL and added to the cultured cells for 60 min. A MPA-213 
commercial formulation was used as anti-inflammatory non-LP reference formulation 214 
(Medrivas®), and unexposed cells or cells exposed to the dispersion solution and blank 215 
LP formulation were used as controls. After the exposure period, the cells were washed 216 
3 times in phosphate buffered saline (PBS) and fresh serum-free culture medium was 217 
added.  218 
 219 
2.5. Cytotoxicity assay 220 
To measure potential formulation toxicity, the XTT (2,3-bis-(2-methoxy-4-nitro-5-221 
sulfophenyl)-2H-tetrazolium-5-carboxanilide) cytotoxicity assay was used. After the 222 
exposure period, the XTT reagent was added according to manufacturer´s instructions 223 
and absorbance read. At least 3 independent experiments in triplicates were 224 
performed. Benzalkonium chloride (BAC) at 0.001% was used as positive cytotoxicity 225 
control. The percentage of viable cells relative to control cells was determined.  226 
 227 
2.6. Liposomal formulation uptake by HCE cells and localization in ex vivo porcine 228 
corneas 229 
The C6-LP was quantified and localized by fluorometry and fluorescence 230 
microscopy, respectively. To ensure that the fluorescence originated from C6-LP, a C6 231 
suspension was used as the control. For fluorometry determinations, HCE cells were 232 
plated in black 96-well plate and exposed to C6-LP or C6 suspension (not in 233 
liposomes) for 60 min. Then, cells were washed with PBS until the fluorescent signal of 234 
the PBS used for washing cells was the same that fresh PBS. The fluorescent signal 235 
(excitation wavelength: 490 nm; emission wavelength: 520 nm) of the bottom of each 236 
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well was measured at 0, 24, 48, and 72 h after the exposure period. Unlabeled LP 237 
formulation in PBS was used as a blank. For fluorescence microscopy, HCE cells were 238 
plated in multichambered coverslip and exposed to C6-LP or C6 suspension for 60 min 239 
and over washed. Representative micrographs were taken at each time point using 240 
same optimized exposure time, gain, and intensity of the camera. Also, cell uptake was 241 
further characterized immediately after the exposure period. Cell nuclei were 242 
counterstained with Hoechst dye and vertical spatial images were generated by Z-243 
scans. At least 3 independent experiments in triplicates were performed. 244 
In addition, ex vivo porcine corneas were used to localize the LP formulation in the 245 
stratified corneal epithelium and stroma. Porcine eyeballs (n = 3), obtained from a local 246 
slaughterhouse, were washed with povidone iodine solution and PBS. Then, a 12-mm 247 
diameter silicon ring was placed on the central cornea, and a C6-LP or C6 suspension 248 
(not in liposomes) was applied for 5 and 60 min. Unlabeled blank LP formulation at the 249 
same exposure period was used as control. After the exposure, the eyeballs were 250 
washed with PBS and placed in 2.5% buffered paraformaldehyde. The central cornea 251 
was isolated and embedded in optimal cutting temperature compound and frozen. 252 
Representative micrographs of cryostat sections (5 µm) were taken using the same 253 
optimized exposure time, gain, and intensity for each group of samples. At least 3 254 
independent experiments were performed. 255 
 256 
2.7. Protein expression analysis by electrophoresis and Western blotting 257 
Cells were homogenized in ice-cold radioimmunoprecipitation assay buffer plus 258 
protease inhibitors, and the protein content was quantified. Total protein was heated at 259 
100˚C, and 15 µg of protein from each sample was separated by sodium dodecyl 260 
sulfate-polyacrylamide gel electrophoresis. Proteins were subsequently transferred to 261 
nitrocellulose membranes, and incubated with a blocking solution composed of tris-262 
buffered saline containing 0.05% Tween-20, 5% powdered milk, and 2.5% bovine 263 
serum albumin for 60 min. The membranes were incubated with 2.5 µg/mL of primary 264 
antibodies in blocking solution overnight at 4°C and with peroxidase-conjugated 265 
secondary antibodies for 60 min. Receptor protein expression was normalized to 266 
GAPDH expression. At least 3 independent experiments in duplicates were performed. 267 
 268 
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2.8. Glucocorticoid receptor and progesterone receptor localization by 269 
immunofluorescence analysis 270 
Some HCE cultures were fixed in ice-cold methanol immediately after exposure to 271 
the liposomal formulations and kept at -20˚C while others were fixed 24 h after LP 272 
exposure. Slides were washed in PBS and incubated with 0.3% Triton X-100 for 10 273 
min. The slides were incubated at room temperature for 60 min in PBS with 4% donkey 274 
serum. They were then incubated with 5 µg/mL of primary antibodies against 275 
glucocorticoid and progesterone receptors overnight at 4°C. Alexa Fluor 488-276 
conjugated secondary antibody was incubated for 60 min at room temperature. Cell 277 
nuclei were counterstained with propidium iodide. Negative controls omitted the 278 
primary antibodies (isotype control). Micrographs were taken using the same optimized 279 
exposure time, gain, and intensity of the camera. To calculate percentage of nuclear 280 
receptor fluorescence, green (receptor) and red (nuclei) channels were thresholded. 281 
The percentage of nuclear translocation was calculated using the following formula: 282 
%	nuclear	fluorescence =
receptor	fluorescence	localized	in	nuclear	area
total	receptor	fluorescence
	100 
Where the receptor fluorescence (green) localized in the nuclear area (demarcated by 283 
red) were the mean grey value of the thresholded green channel under the thresholded 284 
red channel and the total receptor fluorescence was the mean grey value of the 285 
thresholded green channel. The values were obtained from 4 independent 286 
experiments.  287 
 288 
2.9. Cell proliferation assay 289 
To determine possible changes in cell proliferation rate by MPA-LP exposure, the 290 
alamarBlue® cell proliferation assay was performed at 24, 48, and 72 h after the 291 
exposure period. Fluorescence was read according to manufacturer´s instructions. At 292 
least 3 independent experiments in duplicates were performed. The percentage of 293 
proliferation in treated cultures compared with values for untreated control cells at 24 h 294 
was determined. 295 
 296 
2.10. In vitro inflammation model 297 
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To determine if MPA-LP induced an anti-inflammatory response in HCE cells, an in 298 
vitro inflammation model was used as previously described (Enriquez-de-Salamanca et 299 
al. 2008). Briefly, HCE cells were stimulated with 25 ng/mL TNFα for 24 h after a 300 
washing period with supplement-free culture medium. The cells were then exposed to 301 
blank LP, MPA-LP, and the reference formulation (Medrivas®). The cells were washed 302 
with PBS and fresh medium was added. Cell supernatants were collected 48 h after the 303 
exposure period, and IL-6 and IL-8 production quantified with human IL-6 and IL-8 304 
ELISA kits according to manufacturer´s instructions. At least 3 independent 305 
experiments in duplicates were performed. The ratio of each interleukin concentration 306 
to number of cells was calculated by the alamarBlue® assay. 307 
 308 
2.11. Statistical Analyses 309 
Data were expressed as means ± standard errors of the mean (SEM). Student´s t-310 
test was used to compare two groups. For groups with significantly different variances 311 
(F-test), Welch´s correction was done. For more than 2 groups, we performed either a 312 
one-way analysis of variance followed by pairwise comparisons (Tukey´s test) or a 313 
Brown-Forsythe test followed by pairwise comparisons (Games-Howell test), 314 
depending on Levene’s test for homogeneity of variances. Differences were considered 315 
to be significant when p ≤ 0.05.  316 
 317 
3. Results  318 
3.1. Liposomal formulation characterization and biocompatibility 319 
MPA or C6 addition to the LP composition did not change the mean diameter of 320 
liposomes (Fig. 1A, Table 1). MPA and C6 were included in the initial lipid mixture and 321 
passively loaded into the lipid bilayer of the LPs. The encapsulation efficiency was 322 
close to 94% and 89%, respectively.  323 
The mean diameter, pH, osmolarity, and viscosity of blank, MPA- and C6-LP is 324 
shown in Table 1. The LP-based formulations did not show statistically significant 325 
differences in pH, osmolarity, and viscosity compared with the borate-trehalose-326 
buffered LP-free solution (data not shown).  327 
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The percentage of viable HCE cells did not differ significantly from untreated cells 328 
after 60 min of exposure with either blank, MPA-, or C6-LP (Fig. 1B). The reference 329 
formulation (Medrivas®) was well tolerated while the BAC solution caused significant 330 
cell death, as expected.  331 
 332 
3.2. Uptake and localization of LP formulation in vitro by HCE cells and epithelial 333 
localization in ex vivo porcine corneas 334 
The cellular fluorescent signal was significantly higher after exposure to the C6-LP 335 
than after exposure to the C6 suspension at all times of analysis (Fig. 2A). However, 336 
C6 suspension can also interact with plasmatic membranes and some fluorescence 337 
was detected after sequential cell wash. Z-axis micrographs showed that after C6-LP 338 
exposure for 60 min, the fluorescence was located not only in the cell membrane but 339 
also intracellularly (Fig. 2B). 340 
After 5 min of C6-LP exposure, the ex vivo porcine corneas showed fluorescence 341 
uniformly distributed throughout the corneal epithelium (Fig. 3). In contrast, penetration 342 
of the C6 suspension was largely limited to the outermost epithelial cells. After 60 min 343 
of exposure, the corneal stroma also showed fluorescent signal. However, the C6 344 
suspension-associated fluorescence was weaker and localized only in the outermost 345 
corneal epithelial layers, supporting the permeation of the LP formulation through the 346 
cornea. There was no fluorescent signal associated with unlabeled LP formulation at 347 
any time analyzed.  348 
 349 
3.3. Effect of MPA-LP and reference formulation (Medrivas®) on glucocorticoid and 350 
progesterone receptor protein expression in HCE cells 351 
Glucocorticoid and progesterone receptor protein expression did not differ 352 
immediately after exposure for 60 min (Fig. 4A). However, 24 h after exposure, 353 
progesterone receptor expression was increased after MPA-LP exposure compared 354 
with the control, blank LP-, and reference formulation-exposed cells (Fig. 4B). At that 355 
time point, glucocorticoid receptor expression was decreased in reference formulation-356 
exposed cells compared with control (p = 0.067), blank LP- (p = 0.072), and MPA-LP-357 
exposed cells, although only the latter reached statistical significance (p ≤ 0.05). 358 
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 359 
3.4. Effect of MPA-LP on nuclear translocation of glucocorticoid and progesterone 360 
receptors in HCE cells 361 
There was no measurable nuclear translocation of the glucocorticoid receptor after 362 
exposure for 60 min for any of the LP or reference formulation treatments (Fig. 5A). 363 
However, immediately after the exposure period, nuclear translocation of the 364 
progesterone receptor was higher in MPA-LP-exposed cells than in blank LP-exposed 365 
and untreated cells (Fig. 5B). Twenty-four hours after the exposure, neither the 366 
glucocorticoid receptor nor the progesterone receptor translocation to the nucleus after 367 
MPA-LP exposure was evident (data not shown).  368 
 369 
3.5. Time-dependent effect of MPA-LP on cell proliferation of HCE cells 370 
At 24 h after the exposure period, cell proliferation in MPA-LP-exposed cells was 371 
significantly decreased compared with untreated control cells. At 48 h, the proliferation 372 
of MPA-LP-exposed cells was significantly lower than in blank LP-exposed cells (Fig. 373 
6). Differences in cell proliferation disappeared 72 h after the exposure period. 374 
 375 
3.6. Effect of MPA-LP on IL-6 and IL-8 production by inflamed HCE cells 376 
Prior to determining the anti-inflammatory effect of MPA-LP, changes in 377 
glucocorticoid and progesterone receptors after TNFα stimulation were analyzed by 378 
electrophoresis and Western blotting, and immunofluorescence. Cells stimulated with 379 
TNFα did not show changes in protein expression or translocation of glucocorticoid and 380 
progesterone receptors compared with unstimulated cells (data not shown). 381 
In response to TNFα stimulation for 24 h, the HCE cells increased IL-6 but not IL-8 382 
production 48 h after inflammatory stimulus removal. MPA-LP exposure significantly 383 
reduced both basal and TNFα-induced IL-6 production, reaching unstimulated control 384 
levels (Fig. 7A). The reference formulation (Medrivas®) also reduced IL-6 production in 385 
basal and TNFα-stimulated cells. MPA-LP exposure also significantly reduced IL-8 386 
production compared with the blank LP and reference formulations in TNFα-stimulated 387 
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HCE cells (Fig. 7B). Interestingly, blank LP formulation reduced IL-8 production more 388 
than did the reference formulation. 389 
 390 
4. Discussion 391 
In this work we report that a LP formulation, loaded with an anti-inflammatory drug, 392 
efficiently permeated through corneal epithelial barriers, activated specific drug 393 
receptors, and reduced the production of inflammatory cytokines IL-6 and IL-8 in 394 
cultured HCE cells. The scarcity of anti-inflammatory drugs in the market drove us to 395 
include an anti-inflammatory agent in a LP formulation designed as artificial tears to 396 
treat DED (Vicario-de-la-Torre et al. 2014). We selected the anti-inflammatory hormone 397 
MPA whose properties make it a good steroid-sparing agent, often used to decrease 398 
the dependency of a long-term therapy with steroids in ocular surface inflammatory 399 
diseases.  400 
Taking into account the special requirements for topical ophthalmic formulations, 401 
i.e., pH = 6-9, osmolarity = 150-320 mOsm, viscosity < 20 mPas (Ali and Lehmussaari. 402 
2006, Ammar et al. 2009), the values of our LP-based formulations (Table 1) met all 403 
the requirements to be used as eyedrops. The liposomal formulation was comprised of 404 
components not only similar to those present in the natural tears, such as PC and 405 
cholesterol, but also antioxidants (vitamin E) and molecules able to provide special 406 
benefits for the ocular surface (trehalose) (Li et al. 2012, Pinto-Bonilla et al. 2015). 407 
Also, our liposomal formulation does not contain any preservative, thus avoiding the 408 
well-known harmful side effects associated with them (Baudouin et al. 2010).  409 
We labeled the LP formulation with C6 to localize it in HCE cells and in ex vivo 410 
corneas after 5 and 60 min of exposure. Although the encapsulation efficiency for C6 411 
was always around 90%, free C6 can penetrate through cell membranes. 412 
Consequently, we used a C6 suspension as control to distinguish LP-associated 413 
fluorescence from that caused by C6 in suspension. How the LPs bind to and are 414 
endocytosed by cultured cells has been widely reviewed (Duzgune&scedil et al. 1999, 415 
Lee et al. 1993). LP composition, charge, and size, as well as the types of cells to 416 
which they are exposed, influence the cellular uptake. Therefore, we analyzed cellular 417 
uptake of the LP formulation by HCE cells. It is important to point out that serum was 418 
avoided in all experiments as it partly inhibits the uptake of LPs (Duzgune&scedil et al. 419 
1999). Results showed LP-associated fluorescence in HCE cells immediately, 24, 48, 420 
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and 72 h after 60 min of exposure. Immediately after the exposure period, the cells had 421 
nanometer-sized dots, indicating that the LP did not aggregate in the formulation. 422 
Moreover, these dots corresponding to LPs are within the cell membranes and in the 423 
cytosol, as determined by Z-axis micrographs. This documents the efficient interaction 424 
of the LPs with the cultured cells and confirmed fast uptake by HCE cells in vitro.  425 
To mimic actual in vivo exposure times, C6-LP was in contact with corneal tissues 426 
for only 5 min (Davies. 2000). After C6-LP exposure, the corneas showed fluorescence 427 
through the stratified epithelium, including the basal layers. After 60 min of C6-LP 428 
exposure, the corneal stroma was also stained. We therefore demonstrated that LP 429 
formulation was taken up by all epithelial layers and reached the corneal stroma after 430 
longer exposure times.  431 
MPA binds to progesterone, glucocorticoid, androgen, mineralocorticoid, and 432 
estrogen receptors (Sitruk-Ware. 2004). For this study, we analyzed changes in protein 433 
expression and nuclear translocation of the glucocorticoid and progesterone receptors, 434 
which have greater affinity for the drug (Sitruk-Ware. 2004). Glucocorticoid and 435 
progesterone receptors are closely related members of the steroid receptor family, 436 
which act as ligand-activated transcription factors with well-characterized mechanisms 437 
of action. After binding a specific ligand, the receptors dimerize, and the dimers are 438 
then translocated to the nucleus, allowing the ligand-receptor complex to target specific 439 
DNA sequences (hormone response elements), affecting the inflammatory signaling 440 
cascade (Mangelsdorf et al. 1995). We calculated the percentage of glucocorticoid and 441 
progesterone receptors translocated to the nucleus in immunofluorescence 442 
micrographs as an indicator of receptor activation. Our results showed that while 443 
changes in nuclear translocation were observed immediately after the exposure time, 444 
the protein expression did not change at this time point and the effect of the drug was 445 
observed after 24 h of the exposure time. The progesterone receptor was activated 446 
after MPA-LP exposure, suggesting that MPA was released into cells. The 447 
translocation and the increased expression of the progesterone receptor, but not the 448 
glucocorticoid receptor, after MPA-LP exposure agrees with a study reporting a higher 449 
affinity of MPA for the progesterone receptor than for the glucocorticoid receptor 450 
(Sitruk-Ware. 2004). Unexpectedly, the protein expression of glucocorticoid receptor 451 
was decreased 24 h after reference formulation exposure. This effect may be due to 452 
the vasoconstrictor or the different excipients included in this formulation which 453 
interacts with the glucocorticoid receptor and can modify the expression of this 454 
receptor. It also could explain the lesser effect observed in proliferation or inflammation 455 
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experiments. However, the analysis of the effect caused by those excipients is out of 456 
the scope of this study and more experiments need to be done to clarify this effect. 457 
Corticosteroids affect in vitro cell proliferation; therefore, we analyzed changes in 458 
HCE cell proliferation using a standard proliferation assay. In previous studies, MPA 459 
reduced breast cancer epithelial cell proliferation (Cops et al. 2008, Sutherland et al. 460 
1988), but did not affect corneal fibroblast proliferation (Zhou et al. 2012). Our findings 461 
showed a decrease in the proliferation rate of HCE cells 48 h after MPA exposure, 462 
which further supports efficient MPA transport by the LP formulation to the cells. 463 
To determine the anti-inflammatory effect of MPA-LP in terms of reduction of IL-6 464 
and/or IL-8 production, we optimized a cytokine-induced inflammation model using 465 
HCE cells. TNFα was used as an inflammatory stimulus, and the cytokine IL-6 and the 466 
chemokine IL-8 were used as inflammatory markers. The production of both 467 
inflammatory markers increased after TNFα stimulation in conjunctival epithelial cell 468 
line (Enriquez-de-Salamanca et al. 2008), and both are increased in the tears of 469 
patients with inflammatory diseases (Lam et al. 2009, Massingale et al. 2009). The 470 
production of both cytokines was analyzed 48 h after the exposure of TNFα. This time 471 
point was chosen because changes in the cell proliferation rate emerged 48 h after the 472 
MPA-LP exposure period, with C6-LP-associated fluorescence in the cells. 473 
Furthermore, a previous report using corneal fibroblasts showed MPA-induced collagen 474 
degradation after 36 h of exposure period (Zhou et al. 2012). To rule out a pro-475 
inflammatory effect induced by components of the liposomal formulation (Joffre et al. 476 
2007, Rodriguez and Larrayoz. 2010), blank LP formulation with different cholesterol 477 
concentrations were tested, and no inflammation-associated effects were present (data 478 
not shown). According to our data, the exposure of MPA-LP and the reference 479 
formulation (Medrivas®) reduced IL-6 production by HCE cells. However, only MPA-LP 480 
reduced IL-8 production. Interestingly, blank LP formulation also reduced IL-8 481 
production in comparison to the reference formulation-treated cells and control cells, 482 
although the latter did not reach significance. This result confirms the importance of a 483 
vehicle in drug administration, not only to protect the drug and increase the residence 484 
time in the ocular surface, but also to enhance therapeutic effect of the drug. This is in 485 
agreement with previous data reporting that components of the blank LP formulation, 486 
such as PC, trehalose, and vitamin E down-regulate IL-8 production of different 487 
epithelial cells in vitro (Cejkova et al. 2011, Ekstrand-Hammarstrom et al. 2007, Elisia 488 
and Kitts. 2015, Treede et al. 2009). 489 
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Although the in vitro and ex vivo results obtained with MPA-LP are promising, only in 490 
vivo experiments can evaluate the effect of physiological mechanisms such as the 491 
stress generated by eyelid wiping and tear flow on the liposomal formulation. In 492 
addition, the reference formulation (Medrivas®) contains not only the preservative BAC 493 
but also a vasoconstrictor, tetryzoline chlorhydrate, which might have effects that could 494 
not be assessed with our current in vitro approach. 495 
 496 
5. Conclusions 497 
To conclude, our findings show that an anti-inflammatory agent such as MPA loaded 498 
in the LP formulation permeated ex vivo through corneal barriers and was efficiently 499 
delivered to corneal epithelial cells. Also, the delivered MPA in vitro activated specific 500 
drug receptors and showed anti-proliferative and anti-inflammatory effects in HCE cells. 501 
Consequently, when applied topically as eyedrops, MPA-LP may attach to the 502 
hydrophobic corneal epithelium and continuously release the encapsulated drug, 503 
improving its biodistribution. In addition, the liposomal formulation does not contain 504 
preservatives or other bioactive agents required in the reference formulation, thus 505 
avoiding harmful side effects. In this sense, anti-inflammatory drugs included in 506 
unpreserved artificial tears can be useful for the treatment of inflammatory processes 507 
associated with DED or other ocular surface disorders that involve any inflammatory 508 
surface reactions. 509 
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Figure legends 621 
Figure 1: Diameter size distribution and cytotoxicity. (A) The diameter size 622 
distribution of the liposomal formulation did not change with the addition of MPA or C6 623 
as determined by dynamic light scattering. (B) The percentage of viable cells did not 624 
differ from untreated cells with either blank, MPA- or C6- LP formulations after 60 min 625 
of exposure in HCE cells as measured by the XTT assay. ***P ≤ 0.001 compared with 626 
control. LP: liposome-based formulation; C6-LP: liposome-based formulation loaded 627 
with coumarin-6; MPA-LP: liposome-based formulation loaded with 628 
medroxyprogesterone acetate; BAC: benzalkonium chloride. 629 
Figure 2: Uptake and distribution in human corneal epithelial cells. (A) At all times 630 
analyzed, the cellular fluorescent signal was significantly higher after C6-LP exposure 631 
than after C6 suspension exposure in HCE cells as determined by fluorescence 632 
microscopy (left) and fluorometry (right). (B) After the exposure time, C6-LP was taken 633 
up by HCE cells as Z-scans showed intracellular C6-LP localization. C6 stained in 634 
green and nuclei were stained in blue with Hoechst dye. **P ≤ 0.01; *** P ≤ 0.001, 635 
compared at same time points. LP: liposome-based formulation; C6: coumarin-6; C6-636 
LP: liposome-based formulation loaded with C6. Scale bar: 50 µm. 637 
Figure 3: Localization in ex vivo porcine corneas. C6-LP was uniformly distributed 638 
throughout the corneal epithelium in ex vivo corneas after 5 min and 60 min of 639 
exposure. Arrows show stromal localization of C6-LP after 60 min of exposure in ex 640 
vivo porcine corneas. LP: liposome-based formulation; C6: coumarin-6; C6-LP: 641 
liposome-based formulation loaded with C6. Scale bar: 50 µm. 642 
Figure 4: Changes in the expression of glucocorticoid and progesterone  643 
receptors in human corneal epithelial cells. Although no changes were shown 644 
immediately after (T 0 h) the exposure period (A), MPA-LP-exposed cells increased 645 
progesterone receptor expression compared with control, blank LP, and reference 646 
formulation-exposed cells after 24 h (T 24 h) the exposure period (B), as determined by 647 
electrophoresis and Western blotting. *P ≤ 0.05; **P ≤ 0.01. LP: liposome-based 648 
formulation; MPA-LP: liposome-based formulation loaded with medroxyprogesterone 649 
acetate; GR: glucocorticoid receptor; PR: progesterone receptor; Rs: receptors; 650 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase.  651 
Figure 5: Nuclear translocation (activation) of glucocorticoid and progesterone 652 
receptors in human corneal epithelial cells. Although no changes were shown in 653 
glucocorticoid receptor nuclear translocation (A), MPA-LP-exposed cells increased 654 
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nuclear translocation of progesterone receptor compared with control and blank LP-655 
exposed cells (B) determined by fluorescence microscopy. Receptors stained in green 656 
and nuclei were stained in red with propidium iodide. Graph shows the percentage of 657 
nuclear receptor fluorescence calculated by measuring the receptor staining in the 658 
nuclear area to the total receptor staining. *P ≤ 0.05. LP: liposome-based formulation; 659 
MPA-LP: liposome-based formulation loaded with medroxyprogesterone acetate; GR: 660 
glucocorticoid receptor; PR: progesterone receptor; Iso Con: isotype controls including 661 
omission of primary antibodies. Scale bar: 50 µm. 662 
Figure 6: Changes in corneal epithelial cell proliferation. MPA-LP-exposed cells 663 
reduced cell proliferation compared with blank LP-exposed cells 48 h after the 664 
exposure period as determined by the alamarBlue® assay. *P ≤ 0.05, compared with 665 
control, if not otherwise indicated by straddle bars. LP: liposome-based formulation; 666 
MPA-LP: liposome-based formulation loaded with medroxyprogesterone acetate. 667 
Figure 7: Changes in inflammatory cytokine production in inflamed human 668 
corneal epithelial cells. MPA-LP-exposed cells reduced IL-6 and IL-8 production 669 
compared with control and blank LP-exposed cells 48 h after the exposure period as 670 
determined by ELISA. Note the difference in scales for the y-axes of panels A and B. 671 
*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, compared with control, if not otherwise indicated by 672 
straddle bars. LP: liposome-based formulation; MPA-LP: liposome-based formulation 673 
loaded with medroxyprogesterone acetate; IL: interleukin; TNFα: tumor necrosis factor-674 
alpha. 675 
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Table 1: Liposomal formulation diameter, pH, osmolarity, and viscosity. 
 Blank LP MPA-LP C6-LP 
Diameter (nm) 191.6 ± 2.4 185.5 ± 3.5 188.1 ± 2.0 
pH 7.4 ± 0.1 7.4 ± 0.2 7.5 ± 0.3 
Osmolarity (mOsm) 202.4 ± 0.1 206.0 ± 0.2 206.7 ± 0.3 
Viscosity (mPas) 3.1 ± 1.1 3.0 ± 0.6 3.1 ± 1.0 
LP: liposome-based formulation; C6: coumarin-6; MPA-LP: liposome-based formulation 
loaded with medroxyprogesterone acetate; C6-LP: liposome-based formulation loaded 
with C6.  
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HIGHLIGHTS  
• Medroxyprogesterone was incorporated into a liposomal artificial tear formulation. 
• Encapsulated drug readily penetrates corneal tissue in an ex vivo porcine model. 
• Encapsulated drug exerts anti-inflammatory effects in human corneal cells in vitro. 
• The novel liposomal artificial tears enhance the effect of the drug in vitro. 
 
